A coronary heart disease risk model for predicting the effect of potent antiretroviral therapy in HIV-1 infected men

International Journal of Epidemiology

Volumn 36, Issue 6, 2007, Pages 1309-1318

  May, Margaret ^a   Sterne, Jonathan A C ^a   Shipley, Martin ^b   Brunner, Eric ^b   D'Agostino, Ralph ^c   Whincup, Peter ^d   Ben Shlomo, Yoav ^a   Carr, Andrew ^e   Ledergerber, Bruno ^f   Lundgren, Jens D ^g   Phillips, Andrew N ^b   Massaro, Joseph ^h   Egger, Matthias ^a,i  

^a UNIVERSITY OF BRISTOL   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c Boston University   (United States)

^d ST GEORGE S HOSPITAL   (United Kingdom)

^e UNIVERSITY OF NEW SOUTH WALES   (Australia)

^f UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^g HVIDOVRE HOSPITAL   (Denmark)

^h BOSTON UNIVERSITY   (United States)

ⁱ UNIVERSITY OF BERN   (Switzerland)

Author keywords

Adverse effects; Coronary heart disease; Coronary risk factors; Highly active antiretroviral therapy; Non nucleoside reverse transcriptase inhibitor; Prognosis; Protease inhibitors

Indexed keywords

ANTIRETROVIRUS AGENT; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

CARDIOVASCULAR DISEASE; HUMAN IMMUNODEFICIENCY VIRUS; INFECTIOUS DISEASE; INHIBITOR; RISK FACTOR;

ADULT; AGED; ARTICLE; BODY MASS; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CIGARETTE SMOKING; COHORT ANALYSIS; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE SEVERITY; DRUG EFFECT; DRUG EFFICACY; DRUG POTENCY; DRUG SAFETY; EXTERNAL VALIDITY; FOLLOW UP; HEART INFARCTION; HIGH RISK PATIENT; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; INTERNAL VALIDITY; ISCHEMIC HEART DISEASE; LIFESTYLE MODIFICATION; MAJOR CLINICAL STUDY; MALE; METABOLIC DISORDER; MORALITY; PRACTICE GUIDELINE; PREDICTION; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; RISK MANAGEMENT; STATISTICAL PARAMETERS; SYSTOLIC BLOOD PRESSURE;

ADULT; AGED; ANTI-RETROVIRAL AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CORONARY DISEASE; FOLLOW-UP STUDIES; GREAT BRITAIN; HIV INFECTIONS; HIV-1; HUMANS; MALE; MIDDLE AGED; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RISK ASSESSMENT; RISK FACTORS;

HUMAN IMMUNODEFICIENCY VIRUS 1; VERONICA;

EID: 36949026957     PISSN: 03005771     EISSN: 14643685     Source Type: Journal    
DOI: 10.1093/ije/dym135     Document Type: Article

References (43)

1. Egger M, Hirschel B, Francioli P et al. Impact of new antiretroviral combination therapies in HIV infected patients in Switzerland: Prospective multicentre study. BMJ 1997;315 1194-99.
2. Palella FJ, Delaney KM, Moorman AC et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med 1998;338:853-60.
3. Carr A, Cooper DA. Adverse effects of antiretroviral therapy. Lancet 2000;356:1423-30.
4. Henry K. The case for more cautious, patient-focused antiretroviral therapy. Ann Intern Med 2000;132:306-11.
5. Carr A, Samaras K, Burton S et al. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS 1998;12:F51-58.
6. Friis-Moller N, Weber R, Reiss P et al. Cardiovascular disease risk factors in HIV patients - association with antiretroviral therapy. Results from the DAD study. AIDS 2003;17:1179-93.
7. de Gaetano DK, Rabagliati R, Iacoviello L, Cauda R. HIV infection, HAART, and endothelial adhesion molecules: Current perspectives. Lancet Infect Dis 2004;4:213-22.
8. Riddler SA, Smit E, Cole SR et al. Impact of HIV infection and HAART on serum lipids in men. JAMA 2003;289:2978-82.
9. Kannel WB, Castelli W, Gordon T. Cholesterol in the prediction of atherosclerotic disease. Ann Intern Med 1979;90:85-91.
10. Stamler J, Daviglus ML, Garside DB, Dyer AR, Greenland P, Neaton JD. Relationship of baseline serum cholesterol levels in 3 large cohorts of younger men to long-term coronary, cardiovascular, and all-cause mortality and to longevity. JAMA 2000;284:311-18.
11. Davey Smith G, Shipley M, Marmot MG, Rose G. Plasma cholesterol concentration and mortality. The Whitehall Study. JAMA 1992;267 70-76.
12. Periard D, Telenti A, Sudre P et al. Atherogenic dyslipidemia in HIV-infected individuals treated with protease inhibitors. The Swiss HIV Cohort Study. Circulation 1999;100:700-5.
13. Fontas E, van Leth F, Sabin CA et al. Lipid profiles in HIV-infected patients receiving combination antiretroviral therapy: Are different antiretroviral drugs associated with different lipid profiles? J Infect Dis 2004;189:1056-74.
14. Shaper AG, Pocock SJ, Walker M, Cohen NM, Wale CJ, Thomson AG. British Regional Heart Study: Cardiovascular risk factors in middle-aged men in 24 towns. BMJ 1981;283:179-86.
15. Caerphilly, & Speedwell collaborative heart disease studies. The Caerphilly and Speedwell Collaborative Group. J Epidemiol Community Health 1984;38:259-62.
16. Feinleib M, Kannel WB, Garrison RJ, McNamara PM, Castelli WP. The Framingham offspring study. Design and preliminary data. Prevent Med 1975;4:518-25.
17. Marmot M, Brunner E. Cohort Profile: The Whitehall II study. Int J Epidemiol 2005;34:251-56.
18. Brunner EJ, Marmot MG, Nanchahal K et al. Social inequality in coronary risk: Central obesity and the metabolic syndrome. Evidence from the Whitehall II study. Diabetologia 1997;40:1341-49.
19. Korn EL, Graubard BI, Midthune D. Time-to-event analysis of longitudinal follow-up of a survey: Choice of the time-scale. Am J Epidemiol 1997;15:528-29.
20. Akaike H. A new look at the statistical model identification. IEEE Trans Autom Control AC 1974;19:716-23.
21. Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med 2002;21:1539-58.
22. Royston P, Parmar MK, Sylvester R. Construction and validation of a prognostic model across several studies, with an application in superficial bladder cancer. Stat Med 2004;30:907-26.
23. May M, Royston P, Egger M, Justice AC, Sterne JA. ART Cohort Collaboration. Development and validation of a prognostic model for survival time data: Application to prognosis of HIV positive patients treated with antiretroviral therapy. Stat Med 2003;23 2375-98.
24. Spiegelhalter DJ, Best NG, Carlin BP, Van der Linde A. Bayesian measures of model complexity and fit. J R Statist Soc B 2002;64:1-34.
25. Carr A, Samaras K, Thorisdottir A, Kaufmann GR, Chisholm DJ, Cooper DA. Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor- associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: A cohort study. Lancet 1999;353:2093-99.
26. Kannel WB, Feinleib M, McNamara PM, Garrison RJ, Castelli WP. An investigation of coronary heart disease in families. The Framingham offspring study. Am J Epidemiol 1979;110:281-90.
27. D'Agostino RB, Grundy S, Sullivan L, Wilson P. Validation of the framingham coronary heart disease prediction scores: Results of a multiple ethnic groups investigation. JAMA 2001;286:180-87.
28. Anderson KM, Wilson PWF, Odell P, Kannel WB. An updated coronary risk profile. A statement for health professionals. Circulation 1991; 83:356-62.
29. Empana JP, Ducimetiere P, Arveiler D et al. Are the Framingham and PROCAM coronary heart disease risk functions applicable to different European populations? The PRIME Study. Eur Heart J 2003;24 1903-11.
30. Justice AC, Covinsky KE, Berlin JA. Assessing the generalizability of prognostic information. Ann Intern Med 1999;130:515-24.
31. Harrell FE, Lee KL, Mark DB. Multivariable prognostic models: Issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med 1996;15:361-87.
32. Harjai KJ. Potential new cardiovascular risk factors: Left ventricular hypertrophy, homocysteine, lipoprotein(a), triglycerides, oxidative stress, and fibrinogen. Ann Intern Med 1999;131:376-86.
33. Yusuf S, Hawken S, Ounpuu S et al. Obesity and the risk of myocardial infarction in 27,000 participants from 52 countries: A case-control study. Lancet 2005;366:1640-49.
34. Barbaro G. Cardiovascular manifestations of HIV infection. Circulation 2002;106:1420-25.
35. Henkin Y, Como JA, Oberman A. Secondary dyslipidemia. Inadvertent effects of drugs in clinical practice. JAMA 1992;267:961-68.
36. Friis-Moller N, Reiss P, Sabin CA et al. Class of antiretroviral drugs and the risk of myocardial infarction. N Engl J Med 2007; 356:1723-35.
37. Sterne JA, May M, Bucher HC et al. HAART and the heart: Changes in coronary risk factors and implications for coronary risk in men starting antiretroviral therapy. J Intern Med 2007;261:255-67.
38. Hadigan C, Meigs JB, Wilson PW et al. Prediction of coronary heart disease risk in HIV-infected patients with fat redistribution. Clin Infect Dis 2003;36:909-16.
39. Marrugat J, D'Agostino R, Sullivan L et al. An adaptation of the Framingham coronary heart disease risk function to European Mediterranean areas. J Epidemiol Community Health 2002;57 634-38.
40. Diverse Populations Collaborative Group. Prediction of mortality from coronary heart disease among diverse populations: Is there a common predictive function? Heart 2002;88:222-28.
41. Brindle P, Emberson J, Lampe F et al. Predictive accuracy of the Framingham coronary risk score in British men prospective cohort study. BMJ 2003;327:1267-70.
42. Egger M, May M, Chene G et al. Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: A collaborative analysis of prospective studies. Lancet 2002;360:119-29.
43. Chene G, Sterne JA, May M et al. Prognostic importance of initial response in HIV-1 infected patients starting potent antiretroviral therapy: Analysis of prospective studies. Lancet 2003;362 679-86.